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Antibiotic resistance has been declared one of the greatest threats to To date, we have focused all of the standard analyses of in vitro and
human health in both the developing and Organisation for Economic
Co-operation and Development (OECD) nations. As pan-resistant
strains of common pathogens are being transported around the world,
it is clear that new antibiotics are needed. The current focus is on
multi-drug resistant (MDR) Gram-negative bacteria such as Escherichia
coli and Pseudomonas aeruginosa, but there are many other similarly
clinically challenging species. Many reviews and editorials have
highlighted the recent lack of new antibiotics, and the causes of this sit-
uation are multifactorial but may lie in two or three areas: namely regu-
latory uncertainty, poor economic evaluations and potentially even local
“bad governance” (Collignon et al., 2015). Although the US Senate ap-
proved the GAIN Act in 2012, it did not provide the agency with all the
necessary tools to ensure new candidate agents could be reviewed
using different, potentially quicker and less costly methods. New addi-
tional legislation is currently being reviewed by the US Senate, but until
that is approved, some impediments to antibiotic development remain.
The year 2014 witnessed a plethora of new antibiotics gaining ap-
proval in theUSA, butmostwere for Gram-positive pathogens [tedizolid
(Sivextra), dalbavancin (Dalvance) and oritavancin (Orbactiv)], mainly
active against methicillin-resistant Staphylococcus aureus (MRSA) with
only ceftolozane–tazobactam (Zerbaxa) and ceftazidime–avibactam
(AVYCAZ) approved for infections caused by Gram-negative pathogens.
Current candidates in development for Gram-negative infections in-
clude plazomicin, meropenem-RPX70092 (Carbavance), S-649266 and
several others.
These programs are still fairly conventional in design but perhaps
could be accelerated with the use of additional studies of a pharmaco-
logical nature. Moreover, it is evident that as soon as we begin using a
new drug or class, the bacteria begin to evolve mechanisms to resist
its activity. This can show up as clinical resistance in ﬁve to twelve or
more years but nevertheless the bacteria have this innate ability to
put us back on the starting blocks.
We will describe some pharmacological approaches that could help
slow the inevitable drive to resistance, but we seem unable to totally
avoid this outcome. Perhaps integrating these concepts could provide
new insights into how antibiotics work actually at the site of infection.⁎ Corresponding author.
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colony-forming units (CFU)/ml as the usual convenient inoculum does
not bear much resemblance to the actual number of bacteria known
to be present in infections. For example, it has been established that uri-
nary tract infection occurs at bacterial concentration of 106 CFU/ml
while Frisch et al. (1942) deﬁned pneumococcal pneumonia occurring
with inocula up 1012 CFU/ml. This vast difference in initial inoculum
demonstrates the “convenience” of current standard methods.
Clearly this number of bacteria and attendant inﬂammatory mole-
cules and cells create a protein and immunoglobulin rich environment,
which is rarely replicated in our models. It is evident that certain antibi-
otics are more heavily protein-bound than others, and it is the different
activities in the rather false man-made conditions upon which we
decide doses and regimens of these critically important drugs.
Tschabitscher et al. (Tschabitscher et al., 2008) termed these drugs as
“critical dosemedicinal products” that is drugswhich have narrow ther-
apeutic range. It may be that the range we currently use as our “gold
standard” does not allow us tomimic conditions underwhich evolution
of mutants to become resistant is best represented.
The concept of themutant prevention concentration (MPC) as intro-
duced by Drlica and Zhao (Dong et al., 1999; Zhao and Drlica, 2001) re-
fers to the minimal concentration of antibiotic that will prevent the
selection of ﬁrst step resistant mutants from a large, typical bacterial in-
oculum. This concept underlies consideration of the “Mutant Selection
Window,” which refers to the antibiotic concentration range above
theMIC and below theMPC. Although some have criticized this concept
as simplistic and artiﬁcial, Drlica and Zhao have validated it in an animal
model and Firsov and colleagues have presented several studies that
support it (Firsov et al., 2003, 2004, 2012, 2013, 2015).
In vitro dynamic models have been used for studying the effect of
duration of therapy and resistance emergence and antibiotic combina-
tions with respect to both enhanced efﬁcacy and preventing resistance
selection, moreover in vitro dynamic models could add a dimension to
current antibiotic drug development in providing potential dosing
ranges for clinical trials that might provide optimal antibacterial effect
and minimize the selection of antibiotic-resistant mutants.
As we are aware of inoculum differences between various infected
sites and organisms, we have also learned that the local environment
in terms of free ions, essential proteins and even the local pH can
exert marked effects on activity and resistance selection. A morethe CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/)
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cology, pharmacokinetics and ultimately the association of these with
antibacterial activity and resistance emergence should underpin a
more relevant array of pre-clinical and animal studies to help ensure a
dose is selected for Phase 2 study that is not only safe and efﬁcacious,
but also goes some way to tackling the inevitable resistance selection
we face today. These studies must be undertaken against a range
of clinically relevant isolates plus some laboratory selected mutants
that have not yet reached clinical practice. We must learn to
pressure-test the candidate drug in as many simulations before
moving to clinical trials.
Thus if we havemore conﬁdence in the ﬁnal chosen dose/frequency,
we can move expeditiously to a single, well-designed clinical trial in
Phase 3 in a speciﬁc indication which will be supported by the above
studies. Such a shift shouldmake phase 3 trials more attractive and fea-
sible to pharmaceutical sponsors.
Providing efﬁcacy and some safety is established, it could be feasible
to move to provisional approval pending collection of more safety and
tolerability data. These data would be mandated and the sponsor
would establish a secure data collection method so that on-time data
is available to the Agencies.
To summarize, the need for new antibiotics is essential if we are to
maintain current modern medical practice. However we model our po-
tential drugs in systems that inadequately or incompletely reﬂect the
actual sites of infection where several factors may interact to select for
resistance, reduce efﬁcacy and potentially create an epidemiological
issue as MDR pathogens spread, it is vital that we implement new PK-
PD approaches to harness these factors. More proscribed use of
in vitro dynamic models, Monte Carlo analyses and other pharmacody-
namic and pharmacokinetic evaluations should help us gain a deeper
insight into the possible ramiﬁcations of our current methods. Perhaps
new candidate drugs could utilize the different local conditions to im-
prove their efﬁcacy or suppress resistance selection. However, the po-
tential beneﬁts of these “different” drugs will need to be assessed
from the standpoint of the actual infection site state; otherwise we
might not recognize their possible value in the ﬁght against MDR
pathogens.Disclosure
No payment was received by either author in the writing of this
manuscript. No conﬂicts of interest are reported by both authors.
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